Today’s AI Top Pick: ZTS

Zoetis (ZTS) is the cleanest asymmetric setup in this pool: a high-quality, cash-generative animal-health franchise that has been beaten down to the absolute floor of its 21-bar range on EVERY timeframe (pos_in_21bar_range_pct = 0 on 1h, 4h, 1d and 1wk). You are not chasing — you are buying a 67% ROE, 27.79% profit-margin, 37.57% operating-margin business at fwdPe 10.12 after a -49% one-year drawdown. The screen is doing exactly what a value screen should do: surfacing a compounder at a cyclical valuation trough. The forecast tape confirms the mean-reversion thesis with unusually large magnitudes and rising conviction with horizon. 1d forecasts: +19.2% / +51.5% / +71.6% (short/mid/long). 1wk forecasts: +40.9% / +98.6% / +135.4%. Even the fast timeframes agree (4h +6.1 / +49.2 / +47.4). That is genuine multi-timeframe alignment — not a single-bar outlier — layered on top of a -36.6% 21-bar weekly move and a -40% drawdown from the weekly high. bullish_prob = 1, near_term_bullish = 1. Fundamentals dominate: recom 2.0 is neutral-ish but analyst upside target is +37.7%, roe 67.01, profitMargin 27.79, debtEq 2.86 (manageable for animal health), peg 1.36 (only mild caveat). PEG is the highest among top contenders but the earnings-power-per-dollar-of-price is exceptional at these levels. News flow is constructive rather than a landmine — the Burry-bet + OA pipeline coverage is a positive narrative catalyst into Q2 earnings, not a guidance cut or legal overhang (contrast INTU downgrade, ADMA Q2 miss, FUTU DOJ probe headline). Why TODAY vs. waiting: with price pinned at range lows on every timeframe and RSI 42, the reward-to-risk of a starter here is materially better than waiting for a confirmation candle 5–8% higher. The forecast asymmetry (weekly long-term +135%) versus a clean invalidation level near ~$66 gives you >5:1 R/R on the long horizon and >2:1 on the first bounce.